Journal of
Medical Laboratory and Diagnosis

  • Abbreviation: J. Med. Lab. Diagn.
  • Language: English
  • ISSN: 2141-2618
  • DOI: 10.5897/JMLD
  • Start Year: 2010
  • Published Articles: 51

Full Length Research Paper

In vitro thalidomide does not interfere with the activation of complement by Mycobacterium leprae

Shannon E. J
  • Shannon E. J
  • US Department of Health and Human Services, Health Resources and Services Administration, National Hansen’s Disease Programs, Laboratory Research Branch, Louisiana State University, Baton Rouge, LA, USA.
  • Google Scholar
Sandoval F. G
  • Sandoval F. G
  • US Department of Health and Human Services, Health Resources and Services Administration, National Hansen’s Disease Programs, Laboratory Research Branch, Louisiana State University, Baton Rouge, LA, USA.
  • Google Scholar
Morales M. J
  • Morales M. J
  • US Department of Health and Human Services, Health Resources and Services Administration, National Hansen’s Disease Programs, Laboratory Research Branch, Louisiana State University, Baton Rouge, LA, USA.
  • Google Scholar


  • Article Number - AD138E8785
  • Vol.1(1), pp. 5-10, April 2010
  •  Accepted: 05 March 2010
  •  Published: 30 April 2010

Abstract

One inflammatory event that may be involved in erythema nodosum leprosum (ENL) is the activation of complement, and thalidomide could suppress ENL by inhibiting its activation. To determine if thalidomide inhibits the activation of complement, we first incubated normal serum with Mycobacterium leprae or with zymosan in the presence of thalidomide. Residual functional complement was then determined by defining the dilution of the serum required to lyses 50% of the rabbit antibody sensitized sheep cells (CH50 Assay). Zymosan and M. lepraeactivated complement. The CH50 values in the serum incubated with M. leprae or with zymosan were equivalent to the CH50 values in the serum incubated with M. leprae or zymosan in the presence of thalidomide. Thalidomide did not disrupt the activation of complement by zymosan, a know initiator of complement activation by the alternative pathway, or by M. leprae.

 

Key words: ENL, thalidomide, complement.